Host pharmacogenetics in the treatment of HIV and cancer.

No abstract is available for this paper.

• Publication year

  2006

• Venue

  Current Drug Safety

• Publication date

  Unknown publication date

• Fields of study

  Medicine

• Identifiers
  DOI 10.2174/157488606775252683PMID 18690920
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Polymorphisms of the XRCC1 DNA repair gene in head and neck cancer

  2009cited by this paper
• Antiretroviral treatment of adult HIV infection: 2008 recommendations of the International AIDS Society-USA panel.

  2008cited by this paper
• In vitro studies of the influence of glutathione transferases and epoxide hydrolase on the detoxification of acrylamide and glycidamide in blood.

  2005cited by this paper
• Pharmacogenomics of Fluorouracil, Irinotecan, and Oxaliplatin in Hepatic Metastases of Colorectal Cancer

  2005cited by this paper
• Pharmacogenetic testing: proofs of principle and pharmacoeconomic implications.

  2005influential reference
• Thiopurine methyltransferase (TPMT) genotype and early treatment response to mercaptopurine in childhood acute lymphoblastic leukemia.

  2005cited by this paper
• The effect of baseline CD4 cell count and HIV-1 viral load on the efficacy and safety of nevirapine or efavirenz-based first-line HAART

  2005influential reference
• MS-920: DNA repair gene polymorphisms, diet and colorectal cancer risk in Taiwan.

  2005cited by this paper
• Cancer pharmacogenomics: powerful tools in cancer chemotherapy and drug development.

  2005influential reference
• X-ray repair cross-complementing group 1 polymorphisms and cancer risks in Asian populations: a mini review.

  2005cited by this paper
• Atazanavir plus ritonavir or saquinavir, and lopinavir/ritonavir in patients experiencing multiple virological failures

  2005cited by this paper
• Pharmacology of oxaliplatin and the use of pharmacogenomics to individualize therapy.

  2005cited by this paper
• Pharmacogenetic influences on treatment response and toxicity in colorectal cancer.

  2005cited by this paper
• The Association of XRCC1 Haplotypes and Chromosomal Damage Levels in Peripheral Blood Lymphocyte among Coke-Oven Workers

  2005cited by this paper
• Atazanavir plus ritonavir or saquinavir, and lopinavir/ritonavir in patients experiencing multiple virological failures.

  2005cited by this paper
• Large-scale investigation of base excision repair genetic polymorphisms and lung cancer risk in a multicenter study.

  2005cited by this paper
• Thiopurine methyltransferase enzyme activity determination before treatment of inflammatory bowel disease with azathioprine: effect on cost and adverse events.

  2005cited by this paper
• Potential antiretroviral drug interactions with cyclophosphamide, Doxorubicin, and Etoposide.

  2005cited by this paper
• Influence of ABCB1, ABCC1, ABCC2, and ABCG2 haplotypes on the cellular exposure of nelfinavir in vivo

  2005cited by this paper
• Influence of CYP2B6 polymorphism on plasma and intracellular concentrations and toxicity of efavirenz and nevirapine in HIV-infected patients

  2005cited by this paper
• Predisposition to nevirapine hypersensitivity associated with HLA-DRB1*0101 and abrogated by low CD4 T-cell counts

  2005cited by this paper
• Adherence to trizivir and tenofovir as a simplified salvage regimen is associated with suppression of viraemia and a decreased cholesterol.

  2005cited by this paper
• Polymorphisms in the DNA base excision repair genes APEX1 and XRCC1 and lung cancer risk in Xuan Wei, China.

  2005cited by this paper
• Uridine Diphosphoglucuronosyl Transferase and Methylenetetrahydrofolate Reductase Polymorphisms as Genomic Predictors of Toxicity and Response to Irinotecan-, Antifolate- and Fluoropyrimidine-Based Chemotherapy

  2004cited by this paper
• Pharmacogenetics of inflammatory bowel disease.

  2004cited by this paper
• Analysis of the glutathione S-transferase (GST) gene family

  2004cited by this paper
• Pharmacogenetics of efavirenz and central nervous system side effects: an Adult AIDS Clinical Trials Group study

  2004cited by this paper
• Pharmacogenomics of thymidylate synthase in cancer treatment.

  2004cited by this paper
• UGT1A1 gene variations and irinotecan treatment in patients with metastatic colorectal cancer

  2004cited by this paper
• Genetic Determinants of the Pre‐ and Post‐Azathioprine Therapy Thiopurine Methyltransferase Activity Phenotype

  2004cited by this paper
• Polymorphisms in DNA repair genes, chromosome aberrations, and lung cancer

  2004cited by this paper
• Treatment for adult HIV infection: 2004 recommendations of the International AIDS Society-USA Panel.

  2004cited by this paper
• A randomized trial to investigate the recycling of stavudine and didanosine with and without hydroxyurea in salvage therapy (RESTART).

  2004cited by this paper
• Protease inhibitors potentiate chemotherapy-induced neutropenia.

  2004cited by this paper
• Thiopurine methyltransferase: should it be measured before commencing thiopurine drug therapy?

  2004influential reference
• PharmGKB Update: II. CYP3A5, Cytochrome P450, Family 3, Subfamily A, Polypeptide 5

  2004cited by this paper
• Lack of association between the ITPA 94C>A polymorphism and adverse effects from azathioprine.

  2004cited by this paper
• Comprehensive analysis of thiopurine S-methyltransferase phenotype-genotype correlation in a large population of German-Caucasians and identification of novel TPMT variants.

  2004cited by this paper
• Pharmacogenetics of irinotecan toxicity.

  2004cited by this paper
• Prospective Clinical Trials Using a Pharmacogenetic/Pharmacogenomic Approach

  2004cited by this paper
• XPD and XRCC1 genetic polymorphisms are prognostic factors in advanced non-small-cell lung cancer patients treated with platinum chemotherapy.

  2004cited by this paper
• Treatment for adult HIV infection.

  2004cited by this paper
• Pharmacogenomics in colorectal cancer.

  2003cited by this paper
• DEPLETION OF GLUTATHIONE S -TRANSFERASE P1 INDUCES APOPTOSIS IN HUMAN LUNG FIBROBLASTS

  2003cited by this paper
• What can oncologists learn from HIV?

  2003cited by this paper
• Population pharmacokinetics and effects of efavirenz in patients with human immunodeficiency virus infection

  2003cited by this paper
• Pharmacogenetics of stomach cancer.

  2003cited by this paper
• A Comprehensive Hepatic Safety Analysis of Nevirapine in Different Populations of HIV Infected Patients*

  2003cited by this paper
• The Cytochrome P450 2B6 (CYP2B6) Is the Main Catalyst of Efavirenz Primary and Secondary Metabolism: Implication for HIV/AIDS Therapy and Utility of Efavirenz as a Substrate Marker of CYP2B6 Catalytic Activity

  2003influential reference
• For the good of the patient: risks and benefits of medicines

  2003cited by this paper
• Population pharmacokinetic meta-analysis with efavirenz.

  2002cited by this paper
• Risk factor analysis of hypersensitivity reactions to abacavir.

  2002cited by this paper
• Pharmacogenomic strategies for developing customized chemotherapy in non-small cell lung cancer.

  2002cited by this paper
• Genetic polymorphisms in CYP3A5, CYP3A4 and NQO1 in children who developed therapy-related myeloid malignancies.

  2002cited by this paper
• Effect of coadministration of nelfinavir, indinavir, and saquinavir on the pharmacokinetics of amprenavir

  2002cited by this paper
• UGT1A1*28 polymorphism as a determinant of irinotecan disposition and toxicity

  2002cited by this paper
• The impact of pharmacogenomics on gastrointestinal cancer therapy.

  2002cited by this paper
• Association between presence of HLA-B*5701, HLA-DR7, and HLA-DQ3 and hypersensitivity to HIV-1 reverse-transcriptase inhibitor abacavir.

  2002cited by this paper
• Individual Therapy: New Dawn or False Dawn?

  2001cited by this paper
• Pharmacogenomics: the inherited basis for interindividual differences in drug response.

  2001cited by this paper
• Mechanism of indinavir-induced hyperbilirubinemia.

  2001cited by this paper
• Recommendation for caution with irinotecan, fluorouracil, and leucovorin for colorectal cancer.

  2001cited by this paper
• Hypersensitivity Related to Abacavir in Two Members of a Family

  2001cited by this paper
• Pharmacogenomics: unlocking the human genome for better drug therapy.

  2001cited by this paper
• A Xeroderma pigmentosum group D gene polymorphism predicts clinical outcome to platinum-based chemotherapy in patients with advanced colorectal cancer.

  2001cited by this paper
• Hypersensitivity reactions during therapy with the nucleoside reverse transcriptase inhibitor abacavir.

  2001cited by this paper
• Extensive genetic polymorphism in the human CYP2B6 gene with impact on expression and function in human liver.

  2001cited by this paper
• Interethnic variability in human drug responses.

  2001cited by this paper
• Human UDP-glucuronosyltransferases: metabolism, expression, and disease.

  2000cited by this paper
• Polymorphisms of UDP-glucuronosyltransferase gene and irinotecan toxicity: a pharmacogenetic analysis.

  2000cited by this paper
• XPD polymorphisms: effects on DNA repair proficiency.

  2000cited by this paper
• CYP3A4 promoter variant in Saudi, Ghanaian and Scottish Caucasian populations.

  2000cited by this paper
• Genetic polymorphism of thiopurine methyltransferase and its clinical relevance for childhood acute lymphoblastic leukemia

  2000cited by this paper
• Pharmacogenomics: translating functional genomics into rational therapeutics.

  1999cited by this paper
• Polymorphic expression of the UDP-glucuronosyltransferase UGT1A gene locus in human gastric epithelium.

  1998cited by this paper
• Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection. HIV Outpatient Study Investigators.

  1998cited by this paper
• Association of CYP3A4 genotype with treatment-related leukemia.

  1998cited by this paper
• Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection.

  1998cited by this paper
• Enhanced proteolysis of thiopurine S-methyltransferase (TPMT) encoded by mutant alleles in humans (TPMT*3A, TPMT*2): mechanisms for the genetic polymorphism of TPMT activity.

  1997influential reference
• Mutations at codon 974 of the DPYD gene are a rare event.

  1997cited by this paper
• Mutations at codon 974 of the DPYD gene are a rare event.

  1997cited by this paper
• A controlled trial of two nucleoside analogues plus indinavir in persons with human immunodeficiency virus infection and CD4 cell counts of 200 per cubic millimeter or less. AIDS Clinical Trials Group 320 Study Team.

  1997cited by this paper
• A 24-week open-label Phase I/II evaluation of the HIV protease inhibitor MK-639 (indinavir)

  1996cited by this paper
• Molecular basis of the human dihydropyrimidine dehydrogenase deficiency and 5-fluorouracil toxicity.

  1996cited by this paper
• Thiopurine S-methyltransferase deficiency: two nucleotide transitions define the most prevalent mutant allele associated with loss of catalytic activity in Caucasians.

  1996influential reference
• A single point mutation leading to loss of catalytic activity in human thiopurine S-methyltransferase.

  1995cited by this paper
• Higher activity of polymorphic thiopurine S-methyltransferase in erythrocytes from neonates compared to adults.

  1995cited by this paper
• Azathioprine-induced myelosuppression in thiopurine methyltransferase deficient heart transplant recipient.

  1993cited by this paper
• Genetic basis for a lower prevalence of deficient CYP2D6 oxidative drug metabolism phenotypes in black Americans.

  1993cited by this paper
• Azathioprine-induced myelosuppression in thiopurine methyltransferase deficient heart transplant recipient.

  1993cited by this paper
• Mercaptopurine pharmacogenetics: monogenic inheritance of erythrocyte thiopurine methyltransferase activity.

  1980influential reference

• METHOD Open Access

  2014cites this paper
• The Coriell personalized medicine collaborative pharmacogenomics appraisal, evidence scoring and interpretation system

  2013cites this paper
• Coriell Personalized Medicine Collaborative®: a prospective study of the utility of personalized medicine.

  2010cites this paper
• The Introduction of Pharmacogenetic Screening to HIV Clinical Practice – Potential Benefits and Challenges 13

  2007influential citation